Green light for GSK's lupus 麻薬 in America

By Daily Mail Reporter
Updated:

?

Pharma 巨大（な） GlaxoSmithKline has received a 上げる after America's 麻薬s 監視者 是認するd one of its 可能性のある blockbuster 薬／医学s.

Pills

麻薬s do work: Food and 麻薬 行政 gave the green light to Benlyst

An （a）忠告の／（n）警報 パネル盤 of the Food and 麻薬 行政 gave the green light to Benlysta, the first 治療 for the 病気 Lupus in half a century. This is likely to lead to 十分な regulatory 是認 next month.

株 in Glaxo 殺到するd 29.5p to 1243p on hopes that a 可能性のある multibillion windfall will 相殺する some of the 歳入s GSK is 始める，決める to lose over the coming years as older 薬／医学s lose their 特許 保護.

GSK is also 身を引くing its blockbuster 糖尿病 治療 Avandia from Europe, and is 厳しく 制限するing sales in the US, after it was 設立する to 増加する the 危険 of heart attack.

全世界の sales of Benlysta - developed in 共同 with American biotech Human Genome Sciences - are 予測（する） to 急に上がる to £1.4bn by 2014, with Glaxo taking a 50% 株.

Some links in this article may be (v)提携させる(n)支部，加入者 links. If you click on them we may earn a small （売買）手数料，委託（する）／委員会／権限. That helps us 基金 This Is Money, and keep it 解放する／自由な to use. We do not 令状 articles to 促進する 製品s. We do not 許す any 商業の 関係 to 影響する／感情 our 編集（者）の independence.

Most watched Money ビデオs

{"status":"error","code":"499","payload":"資産 id not 設立する: readcomments comments with assetId=1708141, assetTypeId=1"}